Search clinical trials for: RSV ΔNS2 Δ1313 I1314L Vaccine

Total 110 results

National Institute of Allergy and Infectious Diseases...
Johns Hopkins Bloomberg School of Public Health

Active, not recruiting

Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Children

Respiratory Syncytial Virus Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age

Respiratory Syncytial Virus (RSV)

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Infectivity, Safety, and Immunogenicity of Recombinant Live-Attenuated RSV Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age

Respiratory Syncytial Virus Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants and Children 6 to 24 Months of Age

Respiratory Syncytial Virus Infections

United States
GlaxoSmithKline

Completed

Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccines

Infections, Respiratory Syncytial Virus

Canada
GlaxoSmithKline

Completed

Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women

Respiratory Syncytial Virus Infections

United States, Australia, Germany, Czechia
GlaxoSmithKline

Completed

A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults

Respiratory Syncytial Virus Infections

United States, Belgium
GlaxoSmithKline

Withdrawn

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers

Respiratory Syncytial Virus Infections

Finland, United States, Spain
Sanofi Pasteur, a Sanofi Company

Completed

Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (VAD00001)

Respiratory Syncytial Virus Infection

Honduras, United States, Chile
GlaxoSmithKline

Completed

A Study to Rank Different Dosages of Antigen of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A), Based on Their Immune Response and Safety, When Administered to Healthy Adult Women

Respiratory Syncytial Virus Infections

Germany, Estonia, Belgium, France
Sanofi Pasteur, a Sanofi Company

Recruiting

Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate

Healthy Volunteers | Respiratory Syncytial Virus Infection | Human Metapneumovirus

United States, Puerto Rico
GlaxoSmithKline

Completed

A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants

Respiratory Syncytial Virus Infections

Taiwan, Spain, United States, Italy, Canada, Panama, Mexico, Poland
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and Children

RSV Infection

United States
Novavax
PATH

Completed

RSV-F Vaccine Dose Ranging Study in Young Women

Respiratory Syncytial Virus (RSV)

United States
GlaxoSmithKline

Completed

A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women

Respiratory Syncytial Virus Infections

United States, Germany, Finland
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older

Respiratory Syncytial Virus Immunization

United States, Australia, Puerto Rico
Vaxart

Completed

Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)

Respiratory Syncytial Virus (RSV)

United States
Meissa Vaccines, Inc.

Completed

Study of the Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seropositive Children

Respiratory Syncytial Virus Infections

United States
Meissa Vaccines, Inc.

Completed

Safety and Immune Response to an Investigational Vaccine Against Respiratory Syncytial Virus in Healthy Adults

Respiratory Syncytial Virus Infections

United States
Novavax

Completed

A Phase I Randomized, Observer-Blinded, Dose-Ranging Study in Healthy Subjects 24 to <72 Months of Age

Respiratory Synctial Virus

Canada
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

Respiratory Syncytial Virus Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

Respiratory Syncytial Virus Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

Respiratory Syncytial Virus Infections

United States
Meissa Vaccines, Inc.

Recruiting

Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months

Respiratory Syncytial Virus (RSV)

United States
Blue Lake Biotechnology Inc.

Recruiting

A Study of BLB-201 RSV Vaccine in Infants and Children

Respiratory Syncytial Virus Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immune Response to a Respiratory Syncytial Virus (RSV) Vaccine in Adults, RSV-Seropositive Children, and RSV-Seronegative Infants and Children

Respiratory Syncytial Virus Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

Respiratory Syncytial Virus Infections

United States
GlaxoSmithKline

Completed

A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age

Respiratory Syncytial Virus Infections

United States
Novavax

Completed

Safety Study of Respiratory Syncytial Virus (RSV)-Fusion (F) Protein Particle Vaccine

Respiratory Syncytial Virus Infections

United States
University of Rochester

Active, not recruiting

Immunogenicity of RSV Vaccines in Residents of Long-Term Care Facilities (LTCF)

Respiratory Syncytial Virus (RSV)

United States
Janssen Vaccines & Prevention B.V.

Terminated

A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older (CYPRESS)

Respiratory Tract Diseases | Respiratory Syncytial Viruses

United States
Janssen Pharmaceutical K.K.

Completed

A Study to Evaluate the Single Vaccination of an Adenovirus Serotype 26 Pre-Fusion F (Ad26.preF) Based Respiratory Syncytial Virus (RSV) Vaccine in Japanese Adults Aged 60 Years and Older

Healthy

Japan
GlaxoSmithKline

Terminated

A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years

Herpes Simplex

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate a Range of Dose Levels of an Adenovirus Serotype 26 (Ad26.RSV.preF)-Based Vaccine in Older Adults

Healthy

United States
GlaxoSmithKline

Completed

Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A) in Healthy Women

Respiratory Syncytial Virus Infections

Belgium
Sanofi Pasteur, a Sanofi Company

Recruiting

Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and Older

Healthy Volunteers | Respiratory Syncytial Virus Infection

Australia
Janssen Vaccines & Prevention B.V.

Terminated

A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Years and Older

Respiratory Syncytial Virus-associated Lower Respiratory Tract Disease Prevention

United States
Novavax

Completed

Placebo- Controlled Study to Evaluate the Safety and Immunogenicity of the RSV-F Vaccine in Elderly Adults

Respiratory Syncytial Virus (RSV)

United States
National Cancer Institute (NCI)

Terminated

Vaccine Therapy in Treating Patients With Metastatic Breast Cancer

Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer

United States
National Cancer Institute (NCI)

Terminated

Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer)

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
GlaxoSmithKline

Completed

Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV

Respiratory Syncytial Virus Infections

Finland, Spain, United Kingdom, United States, Thailand, Brazil, Canada, Panama, Italy, Colombia, Mexico, Poland, Turkey
Shenzhen Shenxin Biotechnology Co., Ltd

Not yet recruiting

A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adults

Respiratory Syncytial Virus Infections
Blue Lake Biotechnology Inc.

Completed

Phase 1 Study of BLB-201 Vaccine in Healthy Young and Older Adults

Respiratory Syncytial Virus Infections

United States
Novavax

Completed

A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults

Respiratory Syncytial Virus (RSV)

United States
Novavax

Completed

Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1™ Adjuvants In Clinically-Stable Older Adults

Respiratory Syncytial Viruses

Australia
Novavax

Completed

Safety and Immunogenicity of the RSV-F Vaccine in Older Adults Previously Treated With the Same Vaccine or Placebo in the Prior Year.

Respiratory Syncytial Virus (RSV)

United States
Novavax

Completed

RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly

Respiratory Syncytial Virus (RSV)

United States
Janssen Pharmaceutical K.K.

Terminated

A Study of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26.RSV.preF)-Based Vaccine for Prevention of Respiratory Syncytial Virus (RSV) Mediated- Lower Respiratory Tract Disease (LRTD) in Japanese Participants

Respiratory Syncytial Virus Prevention

Japan
Pfizer

Completed

A PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN

Respiratory Tract Infection

United States, New Zealand, Chile, Argentina, South Africa
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Infectivity, Safety, and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants and Children 6 to 24 Months of Age

Respiratory Syncytial Virus Infections

United States

3

Subscribe